DMII
Drugs Made In America Acquisition II Corp.
Next earnings ≈ Oct 9, 2026 · est. from filing cadence
$10.05
▼ -0.20%$10.05▲ +1.72%
over 1Y
L $9.87EODHDH $10.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.2%
1W-0.4%
1M-0.2%
3M+0.7%
YTD+1.5%
1Y+1.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity -1.00x).
Drugs Made In America Acquisition II Corp. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY25 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | -$488K |
| Net income | $4.19M |
| Diluted EPS | — |
| Net margin | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$640M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield0.7%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$223.00
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-04-01). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-04-222026-04-28open ↗10-KPeriod ending 2025-12-312026-04-15open ↗8-KPeriod ending 2026-03-242026-04-03open ↗NT 10-KPeriod ending 2025-12-312026-04-01open ↗8-KPeriod ending 2026-03-112026-03-17open ↗8-KPeriod ending 2026-03-062026-03-06open ↗8-KPeriod ending 2026-02-282026-03-06open ↗10-QPeriod ending 2025-09-302025-11-18open ↗8-KPeriod ending 2025-10-082025-11-18open ↗NT 10-QPeriod ending 2025-09-302025-11-17open ↗4Period ending 2025-09-262025-10-17open ↗
Frequently asked
- Is Drugs Made In America Acquisition II Corp. (DMII) a buy?
- DMII currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.00x).
- What is Drugs Made In America Acquisition II Corp.'s quality score?
- DMII scores 36.666666666666664/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002040475, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 6:10:04 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.